Cara Therapeutic (CARA)

NASDAQ
Currency in USD
4.6500
+0.0500(+1.09%)
Closed
After Hours
4.65000.0000(0.00%)
CARA Scorecard
Full Analysis
Quickly burning through cash
Fair Value
Day's Range
4.51014.7899
52 wk Range
2.708413.8000
Key Statistics
Edit
Prev. Close
4.6
Open
4.68
Day's Range
4.5101-4.7899
52 wk Range
2.7084-13.8
Volume
11.27K
Average Vol. (3m)
145.63K
1-Year Change
-31.42%
Book Value / Share
0.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CARA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
12.1200
Upside
+160.65%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year
Show more

Cara Therapeutic Company Profile

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Employees
55

Cara Therapeutic SWOT Analysis


Financial Outlook
Cash runway into 2026, but elevated R&D spending raises concerns. Analysts set price targets ranging from $1.00 to $10.00
R&D Progress
KOURAGE 1 Phase 3 trial results expected Q2 2024, potentially accelerating the 2027 launch timeline and 50% probability of approval estimate
Market Opportunity
Analysts project peak sales of $630 million by 2035 for oral DFK in NP, with limited competition providing potential first-mover advantage
Strategic Pivot
Cara Therapeutics narrows focus to oral difelikefalin for notalgia paresthetica, aiming to capitalize on high unmet need and promising Phase 2 data
Read full SWOT analysis

Cara Therapeutic Earnings Call Summary for Q4/2023

  • Cara Therapeutics focuses on notalgia paresthetica treatment, with Phase 2/3 COURAGE I study results expected in Q3 2023
  • Cash runway extended into 2026 despite anticipated restrictions on KORSUVA injection due to reimbursement changes
  • Company considering partnership opportunities for future business development amid reduced demand for KORSUVA in the US
  • Cash and equivalents decreased to $100.8 million from $156.7 million in 2022; G&A expenses flat at $6.6 million for Q4 2023
  • Management confident in clinical and commercial potential of NP program, prioritizing resources on neuropathic pruritus
Last Updated: 03/05/2024, 05:15 AM
Read Full Transcript

Compare CARA to Peers and Sector

Metrics to compare
CARA
Peers
Sector
Relationship
P/E Ratio
−0.2x−3.1x−0.6x
PEG Ratio
−0.01−0.020.00
Price / Book
30.1x0.1x2.6x
Price / LTM Sales
2.4x4.4x3.1x
Upside (Analyst Target)
160.6%185.4%53.6%
Fair Value Upside
Unlock2.6%8.0%Unlock

Analyst Ratings

0 Buy
2 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 12.1200

(+160.65% Upside)

Earnings

Latest Release
Nov 29, 2024
EPS / Forecast
-- / -0.24
Revenue / Forecast
-- / 2.02M
EPS Revisions
Last 90 days

People Also Watch

32.600
QMCO
-15.48%
8.900
APLD
-0.89%
2.2800
KULR
-8.06%
6.86
ALT
+2.24%
2.240
QSI
-11.81%

FAQ

What Is the Cara Therapeutic (CARA) Stock Price Today?

The Cara Therapeutic stock price today is 4.65

What Stock Exchange Does Cara Therapeutic Trade On?

Cara Therapeutic is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Cara Therapeutic?

The stock symbol for Cara Therapeutic is "CARA."

What Is the Cara Therapeutic Market Cap?

As of today, Cara Therapeutic market cap is 21.26M.

What is Cara Therapeutic Earnings Per Share?

The Cara Therapeutic EPS is -20.97.

What Is the Next Cara Therapeutic Earnings Date?

Cara Therapeutic will release its next earnings report on Feb 26, 2025.

From a Technical Analysis Perspective, Is CARA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.